[
  {
    "name": "Danielle Bitterman",
    "role": "Physician-Scientist | AI Clinical Evaluation ...",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/danielle-bitterman-87834b16b",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** As a physician-scientist focused on AI clinical evaluation, you're likely seeing firsthand how the real value in healthcare AI isn't coming from model improvements alone - like how SmarterDx jumped from 81% to 92% AUROC primarily through better expert labeling rather than architectural changes.\n\n**Question:** From your clinical evaluation work, are you finding that the bottleneck for AI adoption is more about having the right domain expertise and evaluation frameworks rather than raw model performance?",
    "full_title": "Danielle Bitterman - Physician-Scientist | AI Clinical Evaluation ..."
  },
  {
    "name": "Yugang Jia, Ph.D MPH",
    "role": "Health AI @ Google & Lecture @ MIT",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/yugang-jia-ph-d-mph-b983b57",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** Given your work on Health AI at Google and teaching at MIT, you're perfectly positioned to evaluate our thesis that \"evaluators + data models are the moat\" in healthcare AI - especially since we're seeing cases like SmarterDX jumping from 81% to 92% AUROC purely through expert labeling improvements, not architectural changes.\n\n**Question:** From Google's perspective on healthcare AI development, do you think LLM accuracy improvements will eventually make these specialized evaluation frameworks obsolete, or will domain expertise always require custom ontologies and labeling?",
    "full_title": "Yugang Jia, Ph.D MPH - Health AI @ Google & Lecture @ MIT"
  },
  {
    "name": "Iman Azimi",
    "role": "Research Scientist, PhD | mHealth, LLM agents, AI",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/imanazimi",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** As a research scientist working on mHealth and LLM agents, you're likely seeing firsthand how the real competitive advantage isn't in model architecture‚ÄîSmarterDX jumped from 81% to 92% AUROC purely through better expert labels and data, not model improvements.\n\n**Question:** In your mHealth research, are you finding that domain-specific evaluation frameworks and curated datasets are becoming more defensible than the underlying AI models themselves?",
    "full_title": "Iman Azimi - Research Scientist, PhD | mHealth, LLM agents, AI"
  },
  {
    "name": "Melanie Dufva, PhD",
    "role": "Clinical Validation | AI/ML SaMD | LinkedIn",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/melaniedufva",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** As someone focused on clinical validation of AI/ML medical devices, you're seeing firsthand what we're observing across healthcare AI - that expert evaluation frameworks often matter more than raw model performance. SmarterDX jumped from 81% to 92% AUROC primarily through better expert labels, not architectural improvements.\n\n**Question:** In your clinical validation work, are you finding that having domain-specific evaluation criteria and expert-labeled datasets creates more defensible competitive advantages than the underlying ML models themselves?",
    "full_title": "Melanie Dufva, PhD - Clinical Validation | AI/ML SaMD | LinkedIn"
  },
  {
    "name": "Carrie Savage Bennette, PhD MPH",
    "role": "Data Scientist & AI/ML Engineer",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/carrie-bennette",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** As a Data Scientist & AI/ML Engineer with your academic background, you've likely seen how model performance often comes down to data quality and evaluation frameworks rather than architecture - like how SmarterDX jumped from 81% to 92% AUROC purely through better expert labeling, not model improvements.\n\n**Question:** In your experience, do you think the focus on LLM capabilities is overshadowing the critical work of building robust evaluation systems and domain-specific data models?",
    "full_title": "Carrie Savage Bennette, PhD MPH - Data Scientist & AI/ML Engineer"
  },
  {
    "name": "Michael Mullarkey, PhD",
    "role": "Machine Learning Engineer - LinkedIn",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/mcmullarkey",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** As a PhD Machine Learning Engineer, you've likely seen how model architecture improvements often get overshadowed by data quality - like how SmarterDx jumped from 81% to 92% AUROC purely through better expert labeling, not a fancier model.\n\n**Question:** From your ML engineering perspective, do you think the current focus on foundation model capabilities is missing the bigger opportunity in specialized evaluators and domain-specific data curation?",
    "full_title": "Michael Mullarkey, PhD - Machine Learning Engineer - LinkedIn"
  },
  {
    "name": "Rohit Shinde",
    "role": "AI, VBC, Payer-Provider Interoperability! - LinkedIn",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/rohitpshinde",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** Given your focus on payer-provider interoperability, I'm curious about your take on our thesis that specialized data models and evaluators are becoming the real moat in healthcare AI - not the underlying LLMs. We're seeing this play out with Cleveland Clinic choosing vendors based on their 300 smart billing data elements rather than LLM capabilities.\n\n**Question:** In your experience with VBC and interoperability, are you seeing payers prioritize vendors who've built robust healthcare-specific evaluation frameworks over those with better foundational models?",
    "full_title": "Rohit Shinde - AI, VBC, Payer-Provider Interoperability! - LinkedIn"
  },
  {
    "name": "Abhishek Shukla",
    "role": "AI-Driven Payer & Provider Transformation",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/abhishekdshukla",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** Given your focus on AI-driven transformation across payers and providers, you're likely seeing firsthand how the real competitive advantage isn't coming from better LLMs, but from having the right evaluation frameworks and domain-specific data models - like how Cleveland Clinic chose their smart billing vendor based on 300 specialized data elements rather than underlying model performance.\n\n**Question:** In your payer transformation work, are you finding that success hinges more on having robust evaluation systems for AI outputs, or are you still seeing organizations get distracted by chasing the latest model capabilities?",
    "full_title": "Abhishek Shukla | AI-Driven Payer & Provider Transformation"
  },
  {
    "name": "Tyler S.",
    "role": "VP of Payer Partnerships | AI-assisted Automation for ...",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/tylerstowell",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** As VP of Payer Partnerships focusing on AI-assisted automation, you're likely seeing firsthand how the real competitive advantage isn't in the AI models themselves, but in the specialized evaluators and data frameworks that make them actually work in healthcare operations‚Äîlike how Cleveland Clinic chose their vendor based on 300 smart billing data elements rather than LLM capabilities.\n\n**Question:** From your payer partnership perspective, are you finding that health plans care more about vendors having the right healthcare-specific data models and evaluation frameworks, or are they still getting distracted by whoever has the \"best\" underlying AI model?",
    "full_title": "Tyler S. - VP of Payer Partnerships | AI-assisted Automation for ..."
  },
  {
    "name": "Dima Gorenshteyn",
    "role": "Director of AI/ML @ Thirty Madison | Healthcare",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/dimagor",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** As Director of AI/ML at Thirty Madison, you're likely seeing firsthand how healthcare AI success hinges more on domain-specific data and evaluation frameworks than raw model performance - similar to how SmarterDX jumped from 81% to 92% AUROC primarily through expert labels rather than architectural improvements.\n\n**Question:** In your experience building AI for healthcare at scale, are you finding that proprietary clinical datasets and evaluation methodologies create stronger competitive moats than the underlying models themselves?",
    "full_title": "Dima Gorenshteyn - Director of AI/ML @ Thirty Madison | Healthcare"
  },
  {
    "name": "Shauna M. Overgaard, Ph.D.",
    "role": "Scaling AI Innovation Through Global ...",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/shaunaovergaard",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** As someone scaling AI innovation globally, you're likely seeing firsthand how the real competitive advantage in AI isn't coming from model improvements, but from proprietary evaluation systems and domain-specific data - like how SmarterDX jumped from 81% to 92% AUROC purely through expert labeling, not better model architecture.\n\n**Question:** In your experience scaling AI across different markets, are you finding that companies with strong evaluation frameworks and contextual data are creating more defensible moats than those just optimizing foundation models?",
    "full_title": "Shauna M. Overgaard, Ph.D. - Scaling AI Innovation Through Global ..."
  },
  {
    "name": "Shuki Licht",
    "role": "VP, Head of AI Technology & Innovation - LinkedIn",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/shukilicht",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** As VP of AI Technology & Innovation, you're likely seeing the shift where AI differentiation comes less from model performance and more from domain-specific evaluation frameworks and curated datasets - like how SmarterDX jumped from 81% to 92% AUROC primarily through expert label curation rather than architectural improvements.\n\n**Question:** In your experience leading AI innovation, are you finding that proprietary evaluators and specialized data models create stronger competitive moats than raw LLM capabilities?",
    "full_title": "Shuki Licht - VP, Head of AI Technology & Innovation - LinkedIn"
  },
  {
    "name": "Brijesh Patel",
    "role": "Head of Innovation and AI at Pyx Health - LinkedIn",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/brijpatel",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** As Head of Innovation and AI at Pyx Health, you're likely seeing firsthand how healthcare AI success depends more on domain expertise than raw model power - similar to how SmarterDX jumped from 81% to 92% AUROC primarily through expert labeling rather than architectural improvements.\n\n**Question:** In your experience deploying AI at Pyx Health, are you finding that your competitive advantage comes more from your healthcare-specific data models and evaluation frameworks, or from the underlying LLM technology itself?",
    "full_title": "Brijesh Patel - Head of Innovation and AI at Pyx Health - LinkedIn"
  },
  {
    "name": "Jacob Shiff",
    "role": "Chief AI & Technology Officer, CMS Innovation Center",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/jacob-shiff",
    "thesis": "Evaluators + Data Models Are the Moat",
    "outreach_angle": "**Hook:** As Chief AI & Technology Officer at CMS Innovation Center, you're likely seeing firsthand how healthcare AI vendors compete - and our research suggests the real differentiation isn't in the models themselves but in specialized evaluators and data architectures. For instance, SmarterDx jumped from 81% to 92% AUROC purely through expert labeling improvements, not better model architecture.\n\n**Question:** Given CMS's role in shaping healthcare AI adoption, are you finding that vendors with domain-specific evaluation frameworks are outperforming those focused primarily on model sophistication?",
    "full_title": "Jacob Shiff - Chief AI & Technology Officer, CMS Innovation Center"
  },
  {
    "name": "Xiaoying Wu",
    "role": "üì¢ Exciting Leadership Opportunity in our R&D Data Science & Digital Health",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/xiaoying-wu-md-ms-75304419",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Pharma will pay premium for trajectory prediction. Trial simulation enables counterfactual analysis: \"What would have happened with different treatment?\" Currently no validated pricing data."
  },
  {
    "name": "Richard Bonneau",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/richard-bonneau-45b8673",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Pharma will pay premium for trajectory prediction. Trial simulation enables counterfactual analysis: \"What would have happened with different treatment?\" Currently no validated pricing data."
  },
  {
    "name": "Shirley Ying",
    "role": "VP, TA & Launch Decision Science, Oncology",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/shirley-ying-0021416",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Pharma will pay premium for trajectory prediction. Trial simulation enables counterfactual analysis: \"What would have happened with different treatment?\" Currently no validated pricing data."
  },
  {
    "name": "Eden Wells",
    "role": "VP, TA & Launch Decision Science, Oncology",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/eden-wells-86a52898",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Pharma will pay premium for trajectory prediction. Trial simulation enables counterfactual analysis: \"What would have happened with different treatment?\" Currently no validated pricing data."
  },
  {
    "name": "Justin Lecher",
    "role": "Strongly recommend opportunity.",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/justin-lecher",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Pharma will pay premium for trajectory prediction. Trial simulation enables counterfactual analysis: \"What would have happened with different treatment?\" Currently no validated pricing data."
  },
  {
    "name": "Debbie Law",
    "role": "Head of Computational Biology and Bioinformatics",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/debbie-law-7030a215",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Pharma will pay premium for trajectory prediction. Trial simulation enables counterfactual analysis: \"What would have happened with different treatment?\" Currently no validated pricing data."
  },
  {
    "name": "Dana-Farber Cancer Institute",
    "role": "Researchers at Dana-Farber have created an AI-based tool that uses tumor gene sequencing data to predict the primary source of a patient‚Äôs cancer.",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/dana-farber-cancer-institute",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Architecture unproven beyond MSK. JEPA validated on one cancer center's data. Transfer to other institutions, cancer types, non-oncology conditions uncertain. Could be overfitting to MSK's patient population."
  },
  {
    "name": "MD Anderson Cancer Center",
    "role": "Unknown",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/mdandersoncancercenter",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Architecture unproven beyond MSK. JEPA validated on one cancer center's data. Transfer to other institutions, cancer types, non-oncology conditions uncertain. Could be overfitting to MSK's patient population."
  },
  {
    "name": "Kelly Merriman",
    "role": "Evolution of the Cancer Registrar in the Era of Informatics",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/kelly-merriman-mph-phd-ctr-99290553",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Architecture unproven beyond MSK. JEPA validated on one cancer center's data. Transfer to other institutions, cancer types, non-oncology conditions uncertain. Could be overfitting to MSK's patient population."
  },
  {
    "name": "Jeremy Warner",
    "role": "Advancing Readership Needs of the Clinical Cancer Informatics Community",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/jeremy-warner-39001512",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Architecture unproven beyond MSK. JEPA validated on one cancer center's data. Transfer to other institutions, cancer types, non-oncology conditions uncertain. Could be overfitting to MSK's patient population."
  },
  {
    "name": "A. Ian Wong",
    "role": "Happy to have received board certification for Clinical Informatics from the American Board of Preventive Medicine (ABPM) - a road started 15 years ago, finally completed!",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/aianwong",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Architecture unproven beyond MSK. JEPA validated on one cancer center's data. Transfer to other institutions, cancer types, non-oncology conditions uncertain. Could be overfitting to MSK's patient population."
  },
  {
    "name": "Aakash Desai",
    "role": "#ehr",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/aakash-desai-md-mph-444b30165",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Architecture unproven beyond MSK. JEPA validated on one cancer center's data. Transfer to other institutions, cancer types, non-oncology conditions uncertain. Could be overfitting to MSK's patient population."
  },
  {
    "name": "Department of Biomedical Informatics",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/dbmi-ucsd",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Architecture unproven beyond MSK. JEPA validated on one cancer center's data. Transfer to other institutions, cancer types, non-oncology conditions uncertain. Could be overfitting to MSK's patient population."
  },
  {
    "name": "Juan C. Rojas",
    "role": "Leveraging Data to Improve Health Equity and Care",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/juan-c-rojas-md-ms-3a7345190",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Data requirements may be insurmountable for startups. World models need longitudinal data at scale. Epic has 100B events. HIPAA/consent barriers could block multi-institution aggregation for startups."
  },
  {
    "name": "Current Executive Searches",
    "role": "Make the most of your professional life",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/current-executive-searches",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Data requirements may be insurmountable for startups. World models need longitudinal data at scale. Epic has 100B events. HIPAA/consent barriers could block multi-institution aggregation for startups."
  },
  {
    "name": "Vanderbilt University Medical Center",
    "role": "Mize named Chief Medical Information Officer",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/vanderbilt-university-medical-center",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Data requirements may be insurmountable for startups. World models need longitudinal data at scale. Epic has 100B events. HIPAA/consent barriers could block multi-institution aggregation for startups."
  },
  {
    "name": "David Arnold PhD",
    "role": "I‚Äôm happy to share that I‚Äôm starting a new position as Chief Data‚Ä¶",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/david-arnold-phd-c-3027792a",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Data requirements may be insurmountable for startups. World models need longitudinal data at scale. Epic has 100B events. HIPAA/consent barriers could block multi-institution aggregation for startups."
  },
  {
    "name": "Baptist Health",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/baptisthealthsf",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Data requirements may be insurmountable for startups. World models need longitudinal data at scale. Epic has 100B events. HIPAA/consent barriers could block multi-institution aggregation for startups."
  },
  {
    "name": "Mount Sinai Department of Medicine",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/mount-sinai-department-of-medicine",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Data requirements may be insurmountable for startups. World models need longitudinal data at scale. Epic has 100B events. HIPAA/consent barriers could block multi-institution aggregation for startups."
  },
  {
    "name": "Mouneer Odeh",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/mouneerodeh",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Data requirements may be insurmountable for startups. World models need longitudinal data at scale. Epic has 100B events. HIPAA/consent barriers could block multi-institution aggregation for startups."
  },
  {
    "name": "Lee Carmen",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/lee-carmen-5ab5094",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Data requirements may be insurmountable for startups. World models need longitudinal data at scale. Epic has 100B events. HIPAA/consent barriers could block multi-institution aggregation for startups."
  },
  {
    "name": "Alda Mizaku",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/aldamizaku",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Data requirements may be insurmountable for startups. World models need longitudinal data at scale. Epic has 100B events. HIPAA/consent barriers could block multi-institution aggregation for startups."
  },
  {
    "name": "Vinay Vaidya",
    "role": "Want to make a meaningful impact on clinical quality, safety, population‚Ä¶",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/vvaidya",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Data requirements may be insurmountable for startups. World models need longitudinal data at scale. Epic has 100B events. HIPAA/consent barriers could block multi-institution aggregation for startups."
  },
  {
    "name": "Olivia Kew-Fickus",
    "role": "We need an experienced Data Architect!",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/olivia-kew-fickus-53aa3023",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Data requirements may be insurmountable for startups. World models need longitudinal data at scale. Epic has 100B events. HIPAA/consent barriers could block multi-institution aggregation for startups."
  },
  {
    "name": "Ashok Kurian",
    "role": "Career",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/ashok-kurian-40081022",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "Data requirements may be insurmountable for startups. World models need longitudinal data at scale. Epic has 100B events. HIPAA/consent barriers could block multi-institution aggregation for startups."
  },
  {
    "name": "Sarah Gebauer",
    "role": "Benchmarking And Datasets For Ambient Clinical Documentation: A Scoping‚Ä¶",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/sarahgebauer",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Bryan Bunning",
    "role": "Excited to share a new study I had the chance to work on as part of my PhD dissertation at the intersection of AI and clinical trials.",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/bryan-bunning",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Luke Yun",
    "role": "Stanford and Microsoft researchers just launched a new standard for testing medical AI across real-world clinical tasks, not just test questions.",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/jeongwook-yun",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Dr Alex Szolnoki",
    "role": "An Evaluation Framework for Clinical Use of LLMs",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/alex-szolnoki",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Roxana Daneshjou",
    "role": "An evaluation framework for clinical use of large language models in‚Ä¶",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/roxanadaneshjou",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Jae Won Joh",
    "role": "An evaluation framework for clinical use of large language models in‚Ä¶",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/jaewonjoh",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Matt Morgan",
    "role": "Microsoft Research just published an important üî• heat check üî• on medical AI:",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/mattmorganmd",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Narges Razavian",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/narges-razavian-512b7635",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Mohan Timilsina",
    "role": "Harmonizing foundation models in healthcare: A comprehensive survey of‚Ä¶",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/mohan-timilsina",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Google Research",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/googleresearch",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Elena Petelos",
    "role": "Medical Hallucination in Foundation Models",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/elena-petelos-9b67644",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Tao Tu",
    "role": "I am honored to be a part of this journey, from Med-PaLM to Med-PaLM 2 and beyond.",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/tao-tu-024a013b",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Michael Wornow",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/michael-wornow",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Yuming Jiang",
    "role": "A vision‚Äìlanguage foundation model for precision oncology - Nature",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/yuming-jiang-3770b1183",
    "thesis": "JEPA World Models Displace LLMs for Clinical Decisions‚ÄîToken Prediction Becomes Liability by 2028",
    "source_question": "LLM reasoning models could close the gap. o3/o4-class reasoning might achieve 60%+ completeness without architectural change. If reasoning alone solves the problem, world model advantage disappears."
  },
  {
    "name": "Nigam Shah",
    "role": "We are recruiting for #datascience at Stanford Health Care to bring #machinelearning into clinical use, safely, ethically and cost-effectively.",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/nigam",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Execution layer is commoditizing faster than instruments. pi0 open-sourced with 1-20 hours fine-tuning data sufficient for new tasks. Kosmos AI Scientist does 6 months PhD work in 1 day. Computational bottleneck clearing‚Äîwet lab hardware is the constraint. ([[Open Sourcing œÄ0]], [[Kosmos An AI Scientist for Autonomous Discovery]])"
  },
  {
    "name": "Louisa Jorm",
    "role": "UNSW Centre for Big Data Research in Health (CBDRH) is very much looking forward to moving to the HTH later this year!",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/louisa-jorm-11249b166",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Execution layer is commoditizing faster than instruments. pi0 open-sourced with 1-20 hours fine-tuning data sufficient for new tasks. Kosmos AI Scientist does 6 months PhD work in 1 day. Computational bottleneck clearing‚Äîwet lab hardware is the constraint. ([[Open Sourcing œÄ0]], [[Kosmos An AI Scientist for Autonomous Discovery]])"
  },
  {
    "name": "NHS Transformation Directorate",
    "role": "NHS research on AI tools for healthcare",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/nhs-transformation-directorate",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Execution layer is commoditizing faster than instruments. pi0 open-sourced with 1-20 hours fine-tuning data sufficient for new tasks. Kosmos AI Scientist does 6 months PhD work in 1 day. Computational bottleneck clearing‚Äîwet lab hardware is the constraint. ([[Open Sourcing œÄ0]], [[Kosmos An AI Scientist for Autonomous Discovery]])"
  },
  {
    "name": "Health Outcomes & Biomedical Informatics",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/health-outcomes-biomedical-informatics",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Execution layer is commoditizing faster than instruments. pi0 open-sourced with 1-20 hours fine-tuning data sufficient for new tasks. Kosmos AI Scientist does 6 months PhD work in 1 day. Computational bottleneck clearing‚Äîwet lab hardware is the constraint. ([[Open Sourcing œÄ0]], [[Kosmos An AI Scientist for Autonomous Discovery]])"
  },
  {
    "name": "Timothy Huerta",
    "role": "As the newly appointed Associate Dean for Research Information Technology‚Ä¶",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/timhuerta",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Execution layer is commoditizing faster than instruments. pi0 open-sourced with 1-20 hours fine-tuning data sufficient for new tasks. Kosmos AI Scientist does 6 months PhD work in 1 day. Computational bottleneck clearing‚Äîwet lab hardware is the constraint. ([[Open Sourcing œÄ0]], [[Kosmos An AI Scientist for Autonomous Discovery]])"
  },
  {
    "name": "Roshan Hussain",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/roshan-hussain-5107b34",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Execution layer is commoditizing faster than instruments. pi0 open-sourced with 1-20 hours fine-tuning data sufficient for new tasks. Kosmos AI Scientist does 6 months PhD work in 1 day. Computational bottleneck clearing‚Äîwet lab hardware is the constraint. ([[Open Sourcing œÄ0]], [[Kosmos An AI Scientist for Autonomous Discovery]])"
  },
  {
    "name": "Kevin Mahoney",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/kevinbmahoney",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Execution layer is commoditizing faster than instruments. pi0 open-sourced with 1-20 hours fine-tuning data sufficient for new tasks. Kosmos AI Scientist does 6 months PhD work in 1 day. Computational bottleneck clearing‚Äîwet lab hardware is the constraint. ([[Open Sourcing œÄ0]], [[Kosmos An AI Scientist for Autonomous Discovery]])"
  },
  {
    "name": "UCI Health",
    "role": "Dr. Deepti Pandita has been recognized as a chief medical information‚Ä¶",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/uc-irvine-medical-center",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Execution layer is commoditizing faster than instruments. pi0 open-sourced with 1-20 hours fine-tuning data sufficient for new tasks. Kosmos AI Scientist does 6 months PhD work in 1 day. Computational bottleneck clearing‚Äîwet lab hardware is the constraint. ([[Open Sourcing œÄ0]], [[Kosmos An AI Scientist for Autonomous Discovery]])"
  },
  {
    "name": "Kandice Bledsaw",
    "role": "Do you have a clinical background, leadership experience, and a passion for quality, data, and analytics?",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/kandicebledsaw",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Execution layer is commoditizing faster than instruments. pi0 open-sourced with 1-20 hours fine-tuning data sufficient for new tasks. Kosmos AI Scientist does 6 months PhD work in 1 day. Computational bottleneck clearing‚Äîwet lab hardware is the constraint. ([[Open Sourcing œÄ0]], [[Kosmos An AI Scientist for Autonomous Discovery]])"
  },
  {
    "name": "Meghan M. Dierks",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/meghan-m-dierks-md-facs-0651992",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Human costs create hard floor that only full automation solves. Even if sequencing were free, low-pass genome costs $20-30 due to humans in loop. Current market $300-400 vs theoretical $100. Can't build venture business running a lab unless you automate the whole thing. ([[Virtue and Tomaz Berisa]])"
  },
  {
    "name": "Business Success Elites",
    "role": "üèÜ Nominate for upcoming editions.",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/businesssuccesselites",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Human costs create hard floor that only full automation solves. Even if sequencing were free, low-pass genome costs $20-30 due to humans in loop. Current market $300-400 vs theoretical $100. Can't build venture business running a lab unless you automate the whole thing. ([[Virtue and Tomaz Berisa]])"
  },
  {
    "name": "Bakul Patel",
    "role": "By now you‚Äôve likely heard about Med-PaLM, Google Health‚Äôs large language model (LLM) designed to provide high quality answers to medical questions.",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/bakul-patel",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Human costs create hard floor that only full automation solves. Even if sequencing were free, low-pass genome costs $20-30 due to humans in loop. Current market $300-400 vs theoretical $100. Can't build venture business running a lab unless you automate the whole thing. ([[Virtue and Tomaz Berisa]])"
  },
  {
    "name": "Seema Verma",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/seema-verma-384b3a5",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Human costs create hard floor that only full automation solves. Even if sequencing were free, low-pass genome costs $20-30 due to humans in loop. Current market $300-400 vs theoretical $100. Can't build venture business running a lab unless you automate the whole thing. ([[Virtue and Tomaz Berisa]])"
  },
  {
    "name": "CEO Outlook Global",
    "role": "OpenAI appoints Ashley Alexander as VP of Health Products",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/ceooutlookglobal",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Human costs create hard floor that only full automation solves. Even if sequencing were free, low-pass genome costs $20-30 due to humans in loop. Current market $300-400 vs theoretical $100. Can't build venture business running a lab unless you automate the whole thing. ([[Virtue and Tomaz Berisa]])"
  },
  {
    "name": "Richard Gray",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/richard-gray-m-d",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Human costs create hard floor that only full automation solves. Even if sequencing were free, low-pass genome costs $20-30 due to humans in loop. Current market $300-400 vs theoretical $100. Can't build venture business running a lab unless you automate the whole thing. ([[Virtue and Tomaz Berisa]])"
  },
  {
    "name": "Matthew Lungren MD MPH",
    "role": "Leading the charge to transform healthcare with advanced AI¬† - Microsoft‚Ä¶",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/mattlungrenmd",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Human costs create hard floor that only full automation solves. Even if sequencing were free, low-pass genome costs $20-30 due to humans in loop. Current market $300-400 vs theoretical $100. Can't build venture business running a lab unless you automate the whole thing. ([[Virtue and Tomaz Berisa]])"
  },
  {
    "name": "Counsel Health",
    "role": "Unknown",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/counselhealth",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Human costs create hard floor that only full automation solves. Even if sequencing were free, low-pass genome costs $20-30 due to humans in loop. Current market $300-400 vs theoretical $100. Can't build venture business running a lab unless you automate the whole thing. ([[Virtue and Tomaz Berisa]])"
  },
  {
    "name": "Rebecca Torrence",
    "role": "OpenAI to launch consumer health apps, sources say",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/rebecca-torrence",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Human costs create hard floor that only full automation solves. Even if sequencing were free, low-pass genome costs $20-30 due to humans in loop. Current market $300-400 vs theoretical $100. Can't build venture business running a lab unless you automate the whole thing. ([[Virtue and Tomaz Berisa]])"
  },
  {
    "name": "Jessica Rose Morley",
    "role": "How to read a paper involving AI in BMJ Medicine",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/jessicarosemorley",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Capital intensity kills returns. Building instruments requires $30-50M before revenue. If consumables model doesn't work for new entrants, it's PE not VC territory."
  },
  {
    "name": "Oliver Aalami",
    "role": "Fantastic work Vicky Bikia, PhD  Creating robust evaluation datasets through real-world clinical data perturbations is crucial for ensuring LLM reliability in healthcare settings - this kind of rigorous testing methodology will help build trust in AI clinical tools.",
    "bucket": "academic",
    "linkedin": "https://www.linkedin.com/in/oliver-aalami-67035",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Capital intensity kills returns. Building instruments requires $30-50M before revenue. If consumables model doesn't work for new entrants, it's PE not VC territory."
  },
  {
    "name": "Marelize Gorgens Prestidge",
    "role": "This is important work. It is excellent that medical device-oriented and‚Ä¶",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/marelizegorgens",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Capital intensity kills returns. Building instruments requires $30-50M before revenue. If consumables model doesn't work for new entrants, it's PE not VC territory."
  },
  {
    "name": "Moucheng Xu",
    "role": "A foundation model for generalizable disease detection from retinal images‚Ä¶",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/moucheng-xu",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Capital intensity kills returns. Building instruments requires $30-50M before revenue. If consumables model doesn't work for new entrants, it's PE not VC territory."
  },
  {
    "name": "Suhana Bedi",
    "role": "#medhelm #aiinhealthcare #foundationmodels",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/suhana-bedi-486a551b5",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Capital intensity kills returns. Building instruments requires $30-50M before revenue. If consumables model doesn't work for new entrants, it's PE not VC territory."
  },
  {
    "name": "Mohammad Malekzadeh",
    "role": "GitHub - Nokia-Bell-Labs/papagei-foundation-model: PaPaGei: Open‚Ä¶",
    "bucket": "industry",
    "linkedin": "https://www.linkedin.com/in/mlkzade",
    "thesis": "Automation-Native Instruments Displace GUI-Era Incumbents‚ÄîNew Instrument Prime Emerges by 2032",
    "source_question": "Capital intensity kills returns. Building instruments requires $30-50M before revenue. If consumables model doesn't work for new entrants, it's PE not VC territory."
  }
]